By admin 
- Fisher Investments Finalizes Strategic Partnership with Advent and ADIA with Completion of Minority Common Stock Investment
- Ontario Teachers’ Joins Goldman Sachs in Strategic Investment in Healthcare Tech Giant Omega
- Here’s When (and How) to Rebalance Your Investment Portfolio
- Hash Global fuels DataDance’s vision with multi-million dollar investment
- Durham begins re-investment in Hayti corridor
Absci (NASDAQ: ABSI) has announced a strategic collaboration with AMD focused on AI drug discovery advancement. The partnership includes a $20 million strategic investment from AMD through a private investment in public equity (PIPE) and will involve deploying AMD Instinct™ accelerators and ROCm™ software to power Absci’s AI drug discovery workloads, including de novo antibody design models.
You are viewing: Absci Secures $20M AMD Investment, Strategic AI Drug Discovery Partnership to Accelerate Innovation
The collaboration aims to enhance Absci’s biological modeling capabilities by providing optimized AI solutions that offer improved performance, reduced infrastructure costs, and faster innovation cycles. The partnership will showcase the performance of AMD’s Instinct accelerators in complex biological applications, including Absci’s IgDesign1 model, which is the first in vitro validated inverse folding model for antibody design.
Absci (NASDAQ: ABSI) ha annunciato una collaborazione strategica con AMD focalizzata sull’avanzamento della scoperta di farmaci tramite l’IA. La partnership include un investimento strategico di 20 milioni di dollari da parte di AMD attraverso un investimento privato in equity pubblica (PIPE) e prevede l’implementazione di acceleratori AMD Instinct™ e del software ROCm™ per sostenere i carichi di lavoro di scoperta di farmaci basati sull’IA di Absci, comprese le modalità di progettazione di anticorpi de novo.
La collaborazione punta a migliorare le capacità di modellazione biologica di Absci fornendo soluzioni IA ottimizzate che garantiscano performance superiori, riduzione dei costi infrastrutturali e cicli di innovazione più rapidi. La partnership metterà in mostra le performance degli acceleratori Instinct di AMD in applicazioni biologiche complesse, inclusa la modalità IgDesign1 di Absci, che è il primo modello di ripiegamento inverso validato in vitro per la progettazione di anticorpi.
Absci (NASDAQ: ABSI) ha anunciado una colaboración estratégica con AMD centrada en el avance del descubrimiento de fármacos mediante IA. La asociación incluye una inversión estratégica de 20 millones de dólares por parte de AMD a través de una inversión privada en capital público (PIPE) y abarcará la implementación de aceleradores AMD Instinct™ y software ROCm™ para potenciar las cargas de trabajo de descubrimiento de fármacos impulsadas por IA de Absci, incluyendo modelos de diseño de anticuerpos de novo.
La colaboración tiene como objetivo mejorar las capacidades de modelado biológico de Absci mediante la provisión de soluciones de IA optimizadas que ofrezcan un mejor rendimiento, reducción de costos de infraestructura y ciclos de innovación más rápidos. La asociación mostrará el rendimiento de los aceleradores Instinct de AMD en aplicaciones biológicas complejas, incluyendo el modelo IgDesign1 de Absci, que es el primer modelo de plegamiento inverso validado in vitro para el diseño de anticuerpos.
Absci (NASDAQ: ABSI)는 AMD와 전략적 협력 관계를 맺고 인공지능(AI) 약물 발견을 발전시키기로 했습니다. 이 파트너십은 AMD가 진행하는 공모주에 대한 사모 투자(PIPE)를 통해 2천만 달러의 전략적 투자를 포함하며, Absci의 AI 약물 발견 작업 부하를 지원하기 위해 AMD Instinct™ 가속기와 ROCm™ 소프트웨어를 배치할 예정입니다. 여기에는 새로운 항체 설계 모델도 포함됩니다.
협력의 목표는 최적화된 AI 솔루션을 제공하여 Absci의 생물학적 모델링 기능을 향상시키고, 성능을 개선하며, 인프라 비용을 줄이고, 혁신 주기를 가속화하는 것입니다. 이 파트너십은 Absci의 IgDesign1 모델과 같은 복잡한 생물학적 응용 분야에서 AMD의 Instinct 가속기의 성능을 선보일 것입니다. IgDesign1 모델은 항체 설계를 위한 최초의 인 비트로 검증된 역 도형 모델입니다.
Absci (NASDAQ: ABSI) a annoncé une collaboration stratégique avec AMD axée sur l’avancement de la découverte de médicaments grâce à l’IA. Le partenariat comprend un investissement stratégique de 20 millions de dollars de la part d’AMD par le biais d’un investissement privé dans des actions publiques (PIPE) et impliquera le déploiement des accélérateurs AMD Instinct™ et du logiciel ROCm™ pour alimenter les charges de travail de découverte de médicaments par IA d’Absci, y compris les modèles de conception d’anticorps de novo.
La collaboration vise à améliorer les capacités de modélisation biologique d’Absci en fournissant des solutions IA optimisées qui offrent de meilleures performances, des coûts d’infrastructure réduits et des cycles d’innovation plus rapides. Le partenariat mettra en avant les performances des accélérateurs Instinct d’AMD dans des applications biologiques complexes, y compris le modèle IgDesign1 d’Absci, qui est le premier modèle de repliement inversé validé in vitro pour la conception d’anticorps.
See more : How to Invest in Oklo (NYSE:OKLO)
Absci (NASDAQ: ABSI) hat eine strategische Zusammenarbeit mit AMD angekündigt, die sich auf den Fortschritt bei der Entdeckung von Arzneimitteln durch KI konzentriert. Die Partnerschaft umfasst eine strategische Investition von 20 Millionen Dollar von AMD durch eine private Investition in öffentliche Aktien (PIPE) und wird die Bereitstellung von AMD Instinct™ Beschleunigern sowie ROCm™ Software zur Unterstützung der KI-Arbeitslasten von Absci bei der Arzneimittelentdeckung, einschließlich neuartiger Antikörperdesignmodelle, beinhalten.
Das Ziel der Zusammenarbeit ist es, die biologischen Modellierungsfähigkeiten von Absci zu verbessern, indem optimierte KI-Lösungen bereitgestellt werden, die eine verbesserte Leistung, reduzierte Infrastrukturkosten und schnellere Innovationszyklen bieten. Die Partnerschaft wird die Leistung der Instinct-Beschleuniger von AMD in komplexen biologischen Anwendungen demonstrieren, einschließlich des IgDesign1-Modells von Absci, das das erste in vitro validierte inverse Faltungsmodell für das Antikörperdesign ist.
Positive
- Secured $20 million strategic investment from AMD
- Partnership provides access to advanced AMD AI computing technology
- Potential for reduced infrastructure costs and faster innovation cycles
- Strategic alignment with major tech player validates Absci’s AI drug discovery platform
Insights
The
This collaboration could accelerate Absci’s path to commercialization and scaling of its AI-driven drug discovery platform. The deal structure as a PIPE suggests a premium valuation and demonstrates institutional confidence in Absci’s technology. The partnership may lead to reduced R&D costs and faster drug development cycles, potentially improving Absci’s cash runway and operational efficiency.
The integration of AMD’s Instinct accelerators and ROCm software represents a significant technological upgrade for Absci’s AI infrastructure. AMD’s hardware is specifically optimized for complex AI workloads, which is important for Absci’s de novo antibody design models. The partnership goes beyond mere hardware provision – it’s a strategic alignment that could give Absci a competitive edge in computational efficiency and accuracy in drug discovery.
The collaboration’s focus on Absci’s IgDesign1 model, particularly its in vitro validated inverse folding capabilities, suggests potential breakthroughs in antibody design accuracy and speed. This technological synergy could significantly reduce the computational bottlenecks in drug discovery, potentially accelerating the development timeline for new therapeutics.
This partnership marks a significant advancement in the biologics development landscape. By leveraging AMD’s high-performance computing capabilities, Absci’s AI-driven approach to antibody design could see substantial improvements in both speed and accuracy. The validation of their IgDesign1 model through in vitro testing already demonstrates the platform’s potential and this collaboration could further enhance its capabilities.
The impact on drug discovery timelines could be substantial, potentially reducing the traditional years-long development process. For investors, this translates to faster potential returns on R&D investments and increased probability of successful drug candidates. The partnership could position Absci as a leading player in the next generation of drug discovery platforms.
See more : Protecting The Investment: The Strategy Behind Gervonta Davis’s Career
VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) — Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power critical AI drug discovery workloads, including Absci’s advanced de novo antibody design models. AMD will also make a
The strategic partnership supports Absci’s mission of creating better biologics for patients, faster by providing optimized AI solutions for complex biological modeling that offer exceptional performance, reduced infrastructure costs, and faster innovation cycles. Absci Founder & CEO Sean McClain will discuss the strategic partnership at the 43rd Annual J.P.Morgan Healthcare Conference on Wednesday January 15th at 4:30pm PT. Absci and AMD will showcase the exceptional performance of AMD’s Instinct accelerators in addressing complex biological applications, including Absci’s proprietary IgDesign1 model, the first in vitro validated inverse folding model for antibody design.
“At Absci, we are always looking for ways to push the boundaries of what’s possible in drug discovery,” said Sean McClain, Founder & CEO of Absci. “This partnership with AMD gives us the unique advantage of working closely with a partner that is deeply committed to supporting our needs while providing the most efficient, innovative AI solutions available. AMD high-performance compute will enable us to further the development of next-generation antibody therapeutics, and we are excited about the potential that this partnership holds to accelerate the future of drug discovery.”
“We are proud to partner with Absci, a company at the forefront of AI-driven drug discovery, to help further accelerate breakthroughs in therapeutics and transform how biologic drugs are developed,” said Mark Papermaster, Executive Vice President and Chief Technology Officer of AMD. “Absci’s groundbreaking work in AI drug discovery is a perfect fit for AMD high-performance computing solutions and software, designed for the most demanding AI workloads.”
About Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
About AMD
For more than 50 years AMD has driven innovation in high-performance computing, graphics, and visualization technologies. Billions of people, leading Fortune 500 businesses, and cutting-edge scientific research institutions around the world rely on AMD technology daily to improve how they live, work, and play. AMD employees are focused on building leadership high-performance and adaptive products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) website, blog, LinkedIn and X pages.
Absci Forward-Looking Statements
Certain statements in this press release that are not historical facts are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “may,” “pursues,” “anticipates,” “plans,” “believes,” “aims,” “potential,” “forecast,” “estimates,” “extends,” “expects,” and “intends,” or similar expressions. Absci intends these forward-looking statements, including express or implied statements regarding acceleration of the future of AI drug discovery, Absci’s leadership in AI drug discovery, Absci’s ability to leverage AMD’s equity investment, and Absci’s ability to create better biologics and develop next generation antibody therapeutics, among others, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and Absci makes this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect Absci’s current views about its plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to it and on assumptions Absci has made. Absci can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond Absci’s control, including, without limitation, risks and uncertainties relating to Absci’s ability to leverage AMD’s investment, effectively collaborate on research, drug discovery and development activities with its partners or potential partners, Absci’s dependence on third parties to support its internal development programs, including for the manufacture and supply of preclinical and clinical supplies of its product candidates or components thereof, its existing and potential partners’ ability and willingness to pursue the development and commercialization of programs or product candidates under the terms of Absci’s partnership agreements, and overall market conditions and regulatory developments that may affect Absci’s and its partners’ activities under these agreements, along with those risks set forth in Absci’s most recent periodic reports filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, Absci assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
Absci Investor Contact
Alex Khan
VP, Finance & Investor Relations
[email protected]
Absci Media Contact
[email protected]
Investor Relations:
Matt Ramsay
AMD Investor Relations
[email protected]
AMD Media Contact
Brandi Martina
AMD Communications
[email protected]
FAQ
How much did AMD invest in Absci (ABSI) through the PIPE transaction?
AMD invested $20 million in Absci through a private investment in public equity (PIPE) transaction.
What technologies will AMD provide to Absci (ABSI) in their strategic collaboration?
AMD will provide Instinct accelerators and ROCm software to power Absci’s AI drug discovery workloads, including de novo antibody design models.
What are the expected benefits of the AMD-Absci (ABSI) partnership?
The partnership is expected to provide optimized AI solutions, improved performance, reduced infrastructure costs, and faster innovation cycles for Absci’s biological modeling.
What specific Absci (ABSI) technology will benefit from AMD’s computing solutions?
Absci’s IgDesign1 model, the first in vitro validated inverse folding model for antibody design, will utilize AMD’s Instinct accelerators.
Source: https://magnacumlaude.store
Category: News